Optimization of a synthetic β-catenin-dependent promoter for tumor-specific cancer gene therapy
Open Access
- 31 July 2004
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 10 (1) , 150-161
- https://doi.org/10.1016/j.ymthe.2004.03.021
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Latest development in viral vectors for gene therapyTrends in Biotechnology, 2003
- Cancer gene therapy: fringe or cutting edge?Nature Reviews Cancer, 2001
- High-Level, β-Catenin/TCF-Dependent Transgene Expression in Secondary Colorectal Cancer TissueMolecular Therapy, 2001
- Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectorsCritical Reviews in Oncology/Hematology, 2001
- Recombinant adenovirus vectors with knobless fibers for targeted gene transferGene Therapy, 2000
- Targeting of adenoviral vectors through a bispecific single-chain antibodyCancer Gene Therapy, 2000
- Cancer gene therapy: hard lessons and new coursesGene Therapy, 2000
- Targeting adenovirusGene Therapy, 2000
- A strategy for enhancing the transcriptional activity of weak cell type-specific promotersGene Therapy, 1998
- Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic TherapyHuman Gene Therapy, 1997